CFAP69

Across TCGA pan-cancer cohorts, CFAP69 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CFAP69 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CFAP69 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP69 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, KIRC, and ESCA are the cancer types where CFAP69 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.140	0.669	<.001	18	view →
KIRC	OS	Median	All	0.249	0.805	.010	12	view →
ESCA	OS	Median	III,IV	0.136	0.573	.023	9	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	DFS	Median	All	0.816	0.632	.030	6	view →
BLCA	DFS	Median	III,IV	0.166	0.471	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CFAP69–LUAD (OS)

Open the LUAD breakdown →